interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Brincidofovir

Generic competition · all medicines · read 12 November 2026

Is there a generic of Brincidofovir, and who makes it?

Brincidofovir appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Brincidofovir2 dosage-form groups in the Orange Book
0generic makers listed
  1. Brincidofovir appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Tembexa. No generic is listed as marketed.

202020252030203501brand 2021data datePatent 9303051 listed to expire 30 July 2034Exclusivity ODE-354 to 4 June 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 4 June 2028Exclusivity ODE-354 Tembexa
  • 30 July 2034Patent 9303051 drug substance

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Tembexa. No generic is listed as marketed.

202020252030203501brand 2021data datePatent 9303051 listed to expire 30 July 2034Patent 10112909 listed to expire 10 October 2034Patent 10487061 listed to expire 10 October 2034Patent 8962829 listed to expire 10 October 2034Patent 9371344 listed to expire 10 October 2034Exclusivity ODE-354 to 4 June 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 4 June 2028Exclusivity ODE-354 Tembexa
  • 30 July 2034Patent 9303051 drug substance
  • 10 October 2034Patent 10112909
  • 10 October 2034Patent 10487061 drug product
  • 10 October 2034Patent 8962829 drug substance
  • 10 October 2034Patent 9371344 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.